IBRX stock forecast targets $12.60 amid promising cancer trials. Check IBRX stock price, earnings, technical analysis, and if IBRX stock is a buy. March 2026 data.
Introduction
ImmunityBio (IBRX) develops cancer immunotherapies and vaccines. It targets hard-to-treat tumors with T-cell therapies. IBRX stock grabs attention after FDA approvals and trial data releases.
Biotech investors watch clinical milestones closely. High rates pressure small caps in 2026, but oncology breakthroughs drive sector gains.
Latest stock Price & Trend
IBRX stock closed at $8.61 on March 6, 2026, last market session. It declined from $9.55 prior close amid 7.3 million shares traded. Five-day trend dropped 15% from $10.44 peak on March 2.
One-month surged 40% from $6 lows on trial news. Three months doubled, six months up 150%. Year-to-date gains exceed 200%. 52-week high $12.43; low $1.83.
Volatile bullish trend reflects biotech swings. Investors see trial catalysts outweighing pullbacks.
Technical Analysis
Support at $8.50 matches recent lows. Resistance near $10 tests recoveries. Support halts downside; resistance caps gains.
RSI around 45 signals neutral territory. MACD shows bearish crossover after rally. RSI spots exhaustion levels; MACD tracks momentum shifts.
50-day average $8.20 below 200-day $6.50—no golden cross. Volume spiked to 40 million on peaks, now cooling. Averages define trends; volume confirms moves.
Analyst Ratings & Price Targets
5 analysts rate Strong Buy. Average target $12.60, implying 46% upside from $8.61. Range spans current levels to higher. No recent changes noted.
Firms highlight Anktiva approval momentum. Strong Buy reflects trial success confidence for risk-tolerant investors.
Insider Activity
Director filed proposed sale of 25,000 shares at $8.70 on Feb 23. Earlier sales at $3.95 levels. No buys reported.
Routine planned sales show caution. Ownership steady, no panic signals.
Valuation Analysis
Trailing P/E negative on -$351 million losses. Forward P/E undefined. Price-to-sales 88x TTM revenue of $113 million.
Revenue exploded 668% YoY from tiny base. EPS -0.38. Free cash flow negative; market cap $10 billion with 1.03 billion shares.
Biotech peers trade at 20-50x sales pre-profits. IBRX fairly valued for pipeline, overvalued on near-term cash burn.
Recent Earnings & Catalysts
Q4 revenue hit $113 million TTM, massive growth. EPS loss narrowed. Next earnings Feb 23, 2026. Shares volatile around reports.
Catalysts: Anktiva BCG approval for bladder cancer. Phase 3 lung cancer data upcoming. Stock surged 40% on trial wins.
Bullish Case
Anktiva launches generate $200 million peak sales. Oncology pipeline fills 5 approvals by 2028. T-cell platform differentiates.
Partnerships accelerate commercialization. Revenue triples on approvals.
Bearish Case
Trial failures crush 80% biotech stocks. Cash burn $300 million yearly. Competition in immunotherapy crowded.
Regulatory delays common. Dilution via offerings likely.
Market Sentiment & Investor Psychology
Short interest data sparse; puts active in March 2026 options. Institutions light at low ownership.
Retail drives volume spikes on news. Momentum dominates fundamentals. Optimistic on catalysts, fearful of misses.
Short-Term Outlook
Bearish MACD eyes $8.50 support test. Volume pickup needed for $10 rebound. Range trading likely pre-earnings.
Medium to Long-Term Outlook
Pipeline success unlocks billion-dollar sales. Cancer immunotherapy grows 15%; IBRX carves niche. Cash funds trials to 2027.
Watchlist—buy on approval dips. Accumulate under $7.
FAQ
Is IBRX stock a buy right now?
Speculative buy for biotech risk-takers.
What is the price target for IBRX stock?
$12.60 average from 5 analysts.
What are major risks for IBRX stock?
Trial failures, dilution, cash burn.
Next IBRX earnings date?
Feb 23, 2026—trial updates key.
IBRX stock forecast 2026?
$12.60 target on Anktiva ramp.
Suggestions
- Compare with Opendoor stock
- See our BCG therapy forecast
- Read our biotech oncology breakdown
Conclusion
Watchlist IBRX stock. Promising pipeline tempts, but biotech risks demand waiting for clinical proof.
Disclaimer: This article is for informational purposes only and not financial advice.